Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprenone to reduce severity of acute GVHD after allogeneic HSCT
jRCTs061210072Completed
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of teprenone in Acute Graft-Versus-Host Disease (aGvHD) and hematopoietic malignancies (2 arms). Primary endpoint: Incidence of severe acute GVHD. Started Mar 2022; status: completed.
02
Drugs
teprenone
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)hematopoietic malignancies
Beyond the preview
Go deeper on jRCTs061210072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210072.